An Overview of NanoCluster Powder Formulation Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

An Overview of NanoCluster Powder Formulation Technology
The authors describe a technique designed to yield low-density powders with a tailored particle-size distribution over a broad range of respiratory flow rates.


Pharmaceutical Technology
Volume 10, Issue 34, pp. 72-78

References

1. J.S. Patton and P.R. Byron, Nat. Rev. Drug Discov. 6 (1), 67–74 (2007).

2. G. Scheuch et al., Adv. Drug Deliv. Rev. 58, 996–1008 (2006).

3. N. Rasenack, H. Steckel, and B.W. Muller, J. Pharm. Sci. 92 (1), 35–44 (2003).

4. M.J. Telkoand and A.J. Hickey, Respir. Care 50, 1209–1227 (2005).

5. C.J. Musante et al., J. Pharm. Sci. 91 (7), 1580–1590 (2002).

6. M. Sakagami, Adv. Drug Deliv. Rev. 58, 1030–1060 (2006).

7. T.M. Crowder et al., Pharm. Res. 19 (3), 239–245 (2002).

8. J.C. Sung, B.L. Pulliam, and D.A. Edwards, Trends Biotechnol. 25 (12), 563–570 (2007).

9. Y.L. Wong et al., Proc. Natl. Acad. Sci. U.S.A. 104, 2591–2595 (2007).

10. J.C. Sung et al., Pharm. Res. 26 (8), 1847–1855 (2009).

11. R. Gupta et al., Aerosol Sci. Technol. 37 (8), 672–681 (2003).

12. X. Li et al., Int. J. Pharm. 303 (1–2), 113–124 (2005).

13. J.D. Rabinowitz, J. Pharmacol. Exp. Ther. 309 (5), 769–775 (2004).

14. R. Damani et al., 15th International Congress of the International Society for Aerosols in Medicine (Perth, Australia, 2005).

15. L. Kemp et al., J. Allergy Clin. Immunol. 123 (3), 729 (2009).

16. E. Derom and R.A. Pauwels, Clin. Pharmacokinet. 44 (8), 815–836 (2005).

17. L. Shi, C.J. Plumley, and C. Berkland, Langmuir 23 (22), 10897–10901 (2007).

18. N. El-Gendy et al., J. Pharm. Sci. 98 (8), 2731–2746 (2009).

19. C. Plumley et al., Int. J. Pharm. 369 (1–2), 136–143 (2009).

20. N. El-Gendy and C. Berkland, Pharm. Res. 26 (7), 1752–1763 (2009).

21. L.J. Peek, L. Roberts, and C. Berkland, Langmuir 24 (17), 9775–9783 (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here